Physician profile
Omar Sadiq
NPI 1508250986
$10,634.54
in general payments reported to CMS, 2019-2025
26 companies · $984 in 2025
The $984 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $143 · 2022: $1,486 · 2023: $1,446 · 2024: $6,576 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,300 · Food and Beverage: $3,465 · Travel and Lodging: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,300.00 |
| Food and Beverage | $3,465.42 |
| Travel and Lodging | $240.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $5,474.56 | 2024 | Airseal, Conmed Dilation, Conmed Generators |
| Apollo Endosurgery US INC | $1,565.73 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Abbvie INC. | $812.17 | 2022-2025 | Rinvoq, Skyrizi, Mavyret |
| Boston Scientific Corporation | $720.26 | 2021-2025 | Exalt Model D, Spyglass, Spyglass Discover |
| Lilly USA, LLC | $445.85 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $282.56 | 2022-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $272.52 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $226.02 | 2022-2024 | Ocaliva |
| Aimmune Therapeutics, INC. | $112.99 | 2023-2024 | |
| Pfizer INC. | $104.31 | 2023-2024 | |
| Qol Medical, LLC | $82.02 | 2023-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $67.57 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.31 | 2022-2023 | Xifaxan |
| Celgene Corporation | $61.00 | 2022-2023 | Zeposia |
| Janssen Biotech, INC. | $54.80 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $49.32 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $40.42 | 2023 | Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.11 | 2023-2024 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $24.15 | 2023 | |
| Ironwood Pharmaceuticals, INC | $22.91 | 2023 | Linzess |
| Mallinckrodt Hospital Products INC. | $22.67 | 2023 | Terlivaz |
| Amgen INC. | $22.59 | 2025 | Uplizna |
| Medtronic, INC. | $21.04 | 2025 | V-Loc 180 |
| Madrigal Pharmaceuticals | $20.00 | 2025 | Rezdiffra |
| Novo Nordisk INC | $15.38 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $13.28 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Sadiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.